发明名称 Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2<i>H</i>-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
摘要 The present invention is directed to processes and intermediates useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea (Compound I), crystalline forms and solvate forms thereof; and compositions comprising 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea, crystalline forms and solvate forms thereof prepared by processes as described herein.
申请公布号 US9126946(B2) 申请公布日期 2015.09.08
申请号 US200913126563 申请日期 2009.10.27
申请人 Arena Pharmaceuticals, Inc. 发明人 Carlos Marlon;Dong Weitong;Macias Mark;Sato Suzanne Michiko;Selvey Lee Alani
分类号 A61K31/415;C07C231/16;C07D231/16 主分类号 A61K31/415
代理机构 代理人
主权项 1. A process for preparing Form I of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea comprising the step of: converting an acetonitrile solvate of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea to provide said Form I of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea by removing acetonitrile, wherein said converting comprises reducing solvent content at a temperature sufficient to minimize conversion of said acetonitrile solvate to Form II of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea.
地址 San Diego CA US